Biagio Ricciuti: In vivo vulnerabilities to GPX4 and HDAC inhibitors in BRAF V600E lung adenocarcinoma
Biagio Ricciuti shared a post on LinkedIn about his recent paper, commenting:
“Our collaborative effort uncovering in vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-tolerant versus drug-resistant BRAF V600E Lung Adenocarcinoma (LUAD) is out in Cell Reports Medicine. Led by Marie-Julie Nokin, David Santamaria, and Chiara Ambrogio.
Whole-genome CRISPR screening and Ribonucleic acid (RNA) sequencing identified ferroptosis as drug-tolerant persister (DTP) vulnerability in BRAF V600E LUAD.
Persister cells suffered from lipid peroxidation and were sensitive to ferroptosis upon GPX4 inhibition in vivo.
Acquired alterations leading to Mitogen-activated Protein Kinase (MAPK) reactivation enhanced cystine transport to boost GPX4-independent antioxidant responses sensitized tumors to HDAC inhibition.”
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF V600E lung adenocarcinoma published in Cell Reports Medicine.
Additional information
Source: Biagio Ricciuti/LinkedIn
Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School.
His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.